Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults
Public ClinicalTrials.gov record NCT04177355. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Aalum Adjuvants and VRC HIV Env Trimer 4571 and 3M-052-AF With Alum in Healthy, HIV-uninfected Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 BG505 SOSIP.664 gp140 with TLR agonist and/or alum adjuvants in healthy, HIV-uninfected adults.
Study identification
- NCT ID
- NCT04177355
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Interventions
- BG505 SOSIP.664 gp140 Biological
- Placebo Biological
- 3M-052-AF Biological
- CpG 1018 Biological
- GLA-LSQ Biological
- Alum (Aluminum Hydroxide Suspension) Biological
- Trimer 4571 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 13, 2020 (Actual)
- Primary completion
- Nov 4, 2024 (Actual)
- Completion
- Nov 4, 2024 (Actual)
- Last update posted
- Sep 2, 2025
2020 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS | Birmingham | Alabama | 35294 | — |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308-2012 | — |
| The Hope Clinic of the Emory Vaccine Center CRS | Decatur | Georgia | 30030 | — |
| Brigham and Women's Hospital Vaccine CRS (BWH VCRS) | Boston | Massachusetts | 02115-6110 | — |
| Columbia P&S CRS | New York | New York | 10032 | — |
| New York Blood Center CRS (Site 31801) | New York | New York | 10065 | — |
| University of Rochester Vaccines to Prevent HIV Infection CRS | Rochester | New York | 14642 | — |
| Penn Prevention CRS | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh CRS | Pittsburgh | Pennsylvania | 15213 | — |
| Seattle Vaccine and Prevention CRS | Seattle | Washington | 98109-1024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04177355, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04177355 live on ClinicalTrials.gov.